Australia Markets closed

Roche Holding AG (RHHVF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
385.00-12.62 (-3.18%)
At close: 03:06PM EST
Full screen
Trade prices are not sourced from all markets
Previous close397.62
Bid0.00 x 0
Ask0.00 x 0
Day's range393.83 - 399.75
52-week range308.57 - 411.44
Avg. volume4,219
Market cap333.989B
Beta (5Y monthly)0.27
PE ratio (TTM)21.41
EPS (TTM)17.99
Earnings dateN/A
Forward dividend & yield9.78 (2.67%)
Ex-dividend date18 Mar 2021
1y target estN/A
  • GlobeNewswire

    Roche completes purchase agreement with long-term partner TIB Molbiol to expand PCR-test portfolio in the fight against new infectious diseases

    TIB Molbiol excels in ultra-rapid assay development for emerging infectious disease, strongly demonstrated during the COVID-19 pandemicThe acquisition enables Roche to further expand the portfolio of currently over 45 CE-IVD assays and more than 100 research use assays on Roche’s LightCycler PCR instrumentsTIB Molbiol will continue to focus on the research and development of assays that rapidly address critical healthcare needs including biological threats Basel, 1 December 2021 - Roche (SIX: RO

  • Motley Fool

    Could Roche Put a Crinkle in Biogen's Alzheimer's Drug Launch?

    Roche (OTC: RHHBY) is considering a launch of its Alzheimer's disease drug, gantenerumab, at a price that could undercut competition from Biogen's (NASDAQ: BIIB) Aduhelm. In this Motley Fool Live video recorded on Nov. 15, Motley Fool contributors Keith Speights and Brian Orelli discuss reasons why Biogen investors should be concerned if Roche's drug gains FDA approval.

  • Zacks

    4 Reasons Why You Should Add Sarepta (SRPT) to Your Portfolio

    Sarepta's (SRPT) stock creates a significant opportunity for investors on the back of solid demand for its commercialized drugs and steady progress with its key pipeline candidates.